Stock Screener App

Frei -

Installieren

0.5468

1.04% -0.00575

Traws Pharma Inc (TRAW)

Überblick Nachrichten Preisverlauf Forum Prognose

Traws Pharma Inc Aktie (TRAW) Neueste Nachrichten

Why Did TRAW Stock Slump 28% After Hours? - Stocktwits

Traws Pharma Inc (TRAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Traws Pharma prepares MHRA resubmission for influenza study - scanx.trade

H.C. Wainwright Maintains Traws Pharma(TRAW.US) With Hold Rating, Maintains Target Price $1 - Moomoo

Traws Pharma Ties Up To $50 Million Of Additional Financing To Influenza Regulatory And Clinical Milestones - Pulse 2.0

TRAW Reiterated by HC Wainwright & Co. -- Maintains Price Target at $1.00 - GuruFocus

H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 By Investing.com - Investing.com Nigeria

H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 - Investing.com

Traws Pharma shares rise after Q2 loss comes in better than expected - Yahoo Finance

Traws Pharma beats Q2 loss estimates, shares jump 4% By Investing.com - Investing.com South Africa

Traws Pharma beats Q2 loss estimates, shares jump 4% - Investing.com

TRAW Looks 95.6% Undervalued on GF Value™ Amid Price-to-Sales Co - GuruFocus

Ikarian Capital (TRAW) reports 1.56M-share, 9.5% beneficial stake in Traws Pharma - Stock Titan

Traws Pharma Flags Cash Runway Risk Into Q1 2027 Amid FDA Clinical Hold - Minichart

Traws Pharma Reports Q2 Results, Influenza Program Advances - TipRanks

Traws Pharma Q2 Results: EPS beats estimate, losses widen 45% YoY - scanx.trade

Traws Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Traws Pharma, Inc. Q2 2026: Revenue $0 EPS $(0.16) — 10-Q Summary - TradingView

TRAW: Net loss increased, cash is insufficient for 12 months, and Nasdaq delisting risk remains high - TradingView

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights - The Manila Times

Traws Pharma Q2 revenue falls to zero on licensing termination; net loss widens - TradingView

Traws Pharma Reports Q2 2026 Net Loss of $3.0 Million - Quiver Quantitative

Traws Pharma (TRAW) investor Squadron reports 0% beneficial ownership in 13G/A - Stock Titan

Sirenia Capital (TRAW) discloses warrant-based stake capped at 9.9% ownership - Stock Titan

Traws Pharma Inc (NASDAQ: TRAW) Share Price, TRAW Stock News, TRAW Share Price & Updates - Kalkine

Adage Capital reports 4.79% Traws Pharma (TRAW) stake totaling 730,000 shares - Stock Titan

Traws Pharma Q1 2026 Earnings: Net Loss Narrows Sharply, EPS Beats Consensus by 29.78%Analyst Earnings Estimate - dars.gov.et

Traws Pharma Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView

Traws Pharma Inc (TRAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com

Traws Pharma Inc (TRAW) Stock News Today - TradingKey

TRAW Q1 2026 Earnings: Loss Narrows 29.8% Versus Estimates as Pre-Revenue Biotech Holds CourseEPS Consistency Score - vinanet.vn

TRAW Q2'26 Earnings: EPS estimate is (0.34) USD - TradingView

TRAW Moves TRX-100 Through Early Human Testing: What Investors Should Watch - tipranks.com

Traws Pharma, Inc. Files Form 8-K: Company Details, NASDAQ Listing, and Compliance Information (July 2026) - Minichart

Traws Pharma, Inc. Revenue Breakdown – NASDAQ:TRAW - TradingView

Traws Pharma Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Investor SentimentROIC Trend Report - dars.gov.et

Traws Pharma Receives Nasdaq Minimum Bid Price Notice - TipRanks

Traws Pharma Received Notice of Noncompliance - TradingView

Traws Pharma (TRAW) Edges Higher: Micro-Cap Biotech Defends $0.43 SupportHead and Shoulders - vinanet.vn

TRAW Q2'26 Earnings: revenue estimate is 0 USD - TradingView

Traws Pharma Inc (TRAW) Balance Sheet - TradingKey

TRAW|Traws Pharma Inc|Price:0.520|Chg%:+0.032 - TradingKey

Traws Pharma Inc (TRAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

TRAW|Traws Pharma Inc|Price:0.592|Chg%:+0.002 - TradingKey

Traws Pharma Inc (TRAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

TRAW|Traws Pharma Inc|Price:0.546|Chg%:+0.006 - TradingKey

TRAW|Traws Pharma Inc|Price:0.488| - TradingKey

Traws Pharma, Inc. Revenue Breakdown – LS:A40PJ7 - TradingView

Traws Pharma Inc (TRAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Traws Pharma Inc (TRAW) Income Statement - TradingKey

Traws Pharma Inc (TRAW) Cash Flow - TradingKey

Traws Pharma Inc (TRAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Traws Pharma Inc (TRAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Traws Pharma Q1 2026 Earnings: Narrowed Losses Beat Estimates Amid No RevenueEarnings Beat Alert - dars.gov.et

Traws Pharma (TRAW) Slides 10.6% as Selling Pressure IntensifiesMutual Fund Flow - vinanet.vn

Traws Pharma (TRAW) Registration filing Summary - Quartr

Traws Pharma Inc. (TRAW) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Investor SentimentGeographic Revenue Trends - dars.gov.et

RPRX

$60.38

0.61%

INSM

$129.81

3.65%

ROIV

$42.04

0.79%

ALNY

$255.41

1.78%

ONC

$349.89

0.39%

RVMD

$210.19

1.38%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters